Unilever will not raise rejected 50 bln pound bid for GSK consumer arm


GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids "fundamentally undervalued" the business and its prospects. It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.

Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.

U.S.-listed shares of Unilever rose 10.1% on the news, while GSK's fell 2.8%. The two stocks also trade on the FTSE, where the day's trading had closed.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Sustainability is key
Deleum – spending and still yielding
Tourism bound for a pleasant journey
Farm Fresh targets the top shelf
ETF – fishing in deeper waters
Poised for real estate growth
Future of architecture: blending tradition with modern design
Must-have gadgets for rental properties
Ringgit likely to trade on softer note next week
Nasdaq dreams aside, LYC must first focus on profitability

Others Also Read